Search Results
Your search for Matthew Stenger matches 162 pages
Showing 101 - 150POLE-Mutant and Microsatellite-Unstable Endometrial Tumors May Be Candidates for Anti–PD-1 Treatment
In a study reported in JAMA Oncology, Howitt et al found that polymerase e (POLE)-mutant and microsatellite-unstable endometrial tumors may be candidates for anti–PD-1 (programmed cell death protein 1) immunotherapy. Study Details In the study, neoantigen load was predicted on the basis of...
Oral Contraceptives May Offer Long-Term Protection From Endometrial Cancer
In an individual-patient meta-analysis reported in The Lancet Oncology, the Collaborative Group on Epidemiological Studies on Endometrial Cancer found that oral contraceptive use was associated with long-term protection from endometrial cancer. Reduction in risk was greater for carcinomas than...
Addition of Bevacizumab to Standard Chemotherapy Does Not Improve Overall Survival in Newly Diagnosed Ovarian Cancer
Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Oza et al indicate no significant increase with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer. However, overall survival benefit of...
Phase II Trial Shows Activity of mTOR Inhibitor Ridaforolimus in Advanced Endometrial Carcinoma
In a randomized phase II trial reported in the Journal of Clinical Oncology, Oza et al found that the mTOR inhibitor ridaforolimus was active in previously treated advanced endometrial carcinoma. Study Details In the open-label study, 130 patients with progressive disease after one or two lines...
Risk Algorithm Using Serial CA-125 Measurements Increases the Number of Screen-Detected Ovarian Cancers
As reported in the Journal of Clinical Oncology by Menon et al, findings in the United Kingdom Collaborative Trial of Ovarian Cancer Screening indicate that the number of screen-detected ovarian cancers is doubled by using the risk of ovarian cancer algorithm (ROCA) with serial CA-125 measurements...
UK Trial Shows Neoadjuvant Platinum-Based Chemotherapy Noninferior to Adjuvant Chemotherapy in Advanced Ovarian Cancer
In the UK phase III CHORUS trial reported in The Lancet, Kehoe et al found that a strategy of three cycles of platinum-based chemotherapy followed by delayed surgery and three additional cycles of chemotherapy was associated with overall survival noninferior to that achieved with surgery followed...
Second-Line Dovitinib Shows Some Activity in FGFR2-Mutant and FGFR2-Nonmutant Advanced Endometrial Cancer
In a phase II study reported in The Lancet Oncology, Konecny et al found that the multi–tyrosine kinase inhibitor dovitinib appeared to delay progression in some patients as second-line treatment in fibroblast growth factor receptor 2 (FGFR2)-mutant and -nonmutant advanced or metastatic...
Phase II Study Shows Addition of Pazopanib to Paclitaxel Improves Progression-Free Survival in Platinum-Resistant/Refractory Advanced Ovarian Cancer
In an Italian randomized phase II trial reported in The Lancet Oncology, Pignata et al found that the addition of the antiangiogenic multikinase inhibitor pazopanib (Votrient) to weekly paclitaxel significantly improved progression-free survival in patients with platinum-resistant/refractory...
Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells
As reported in the Journal of Clinical Oncology, Stevanovíc et al observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients with metastatic cervical ...
Intraperitoneal Chemotherapy Associated With Long-Term Survival Advantage Over Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Tewari et al found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous chemotherapy in women with advanced ovarian cancer. Study Details The...
No Benefit of Adding Bevacizumab to First-Line Gemcitabine-Docetaxel in Metastatic Uterine Leiomyosarcoma
In a phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Hensley et al found no benefit of adding bevacizumab (Avastin) to first-line gemcitabine-docetaxel in patients with metastatic uterine leiomyosarcoma. Study Details In this...
Complex Surgery Does Not Independently Predict Outcome in Advanced Ovarian Cancer
In an analysis in the Gynecologic Oncology Group (GOG 182) trial population reported in the Journal of Clinical Oncology, Horowitz et al found that more complex surgery was not an independent predictor of progression-free or overall survival among patients with advanced epithelial ovarian or...
Oral Bisphosphonate Use Reduces Risk of Postmenopausal Endometrial Cancer
Bisphosphonate use for treatment or prevention of osteoporosis in postmenopausal women has been associated with a reduced risk of breast cancer, including in a study in the Women’s Health Initiative (WHI) population. In a WHI study reported in the Journal of Clinical Oncology, Newcomb et al...
Meta-Analysis Shows Increased Risk of Ovarian Cancer With Menopausal Hormone Therapy
In a study reported in The Lancet, the Collaborative Group on Epidemiological Studies of Ovarian Cancer found that use of menopausal hormone therapy was associated with an increased risk of ovarian cancer, with the risk being highest among current users. The study consisted of meta-analyses of...
No Reduction in Quality of Life With Addition of Bevacizumab to Chemotherapy in GOG 240 Trial in Advanced Cervical Cancer
The phase III Gynecologic Oncology Group (GOG) 240 trial showed that the addition of bevacizumab (Avastin) to chemotherapy prolonged survival in patients with advanced cervical cancer. An analysis reported in The Lancet Oncology by Penson et al showed no reduction in quality of life among patients...
Phase II Study Shows Activity of Everolimus and Letrozole in Recurrent Endometrial Carcinoma
Interaction of the estrogen receptor and PI3K/AKT/mTOR pathways and the finding of resistance to hormonal therapy mediated by PI3K activation suggest a benefit of adding an mTOR inhibitor to hormonal treatment in endometrial carcinoma. In a phase II study reported in the Journal of Clinical...
Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Frazier et al used data from U.S. and UK clinical trials to identify a high-risk group of patients with pediatric extracranial germ cell tumors. Study Details The study involved data from seven germ cell tumor trials conducted by the...
Cancer Risk Associated With Lynch Syndrome PMS2 Mutation in European Cohort
The effects of PMS2 germline mutations are less well understood than those of other Lynch syndrome–associated mismatch repair gene mutations. In a European cohort study reported in the Journal of Clinical Oncology, ten Broeke et al found that risks of colorectal cancer and endometrial cancer...
High and Increasing 30-Day Hospital Readmission After Surgery for Advanced Ovarian Cancer in Medicare Population
In a study reported in the Journal of Clinical Oncology, Eskander et al found that rates of 30-day hospital readmission after surgery for advanced ovarian cancer are high and have increased significantly in recent years. In the study, the Surveillance, Epidemiology, and End Results (SEER)-Medicare ...
Characterization of Conditional Disease-Free Survival in Patients With Ovarian Cancer
In a study reported in the Journal of Clinical Oncology, Kurta et al calculated conditional disease-free survival estimates among ovarian cancer patients, showing that odds of remaining disease free improve with a longer disease-free period from initial remission. Improved Conditional Disease-Free ...
Low Risk of Breast Cancer After Ovarian Cancer in Women With BRCA Mutation
In a retrospective single-institution study reported in JAMA Surgery, Gangi et al found a low risk of breast cancer after diagnosis of ovarian cancer in women harboring BRCA mutations. The study involved 364 women who had BRCA mutation testing for stage I to IV epithelial ovarian...
Topical Cidofovir and Imiquimod Active in Treating Vulval Intraepithelial Neoplasia
In a UK phase II trial reported in The Lancet Oncology, Tristram et al found that topical cidofovir and topical imiquimod were active in the treatment of vulval intraepithelial neoplasia, suggesting that such treatment may constitute an alternative to surgery. Study Details In the open-label...
Rate of Cancer Detection at Risk-Reducing Salpingo-Oophorectomy
In a study reported in the Journal of Clinical Oncology, Sherman et al found occult cancers in 2.6% of high-risk women undergoing risk-reducing salpingo-oophorectomy. Study Details The study involved 966 asymptomatic high-risk women age ≥ 30 years who underwent risk-reducing...
HPV 16/18 Vaccine Shows Protective Efficacy in Women Aged > 25 Years in 4-Year Interim Follow-up of VIVIANE Study
In the 4-year interim follow-up of the VIVIANE study reported in The Lancet by Skinner et al, the human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine was found to be protective against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CIN1+) associated with...
No Increased Risk of Ovarian Cancer With Perineal Powder Use
Perineal powder use has been associated with increased risk of ovarian cancer in case-control studies and with increased risk of serous invasive ovarian cancer in a cohort study. In a large cohort study reported in the Journal of the National Cancer Institute, Houghton et al found no significant...
Pazopanib Maintenance Improves Progression-Free Survival in Ovarian Cancer, but Benefit Limited to Non–East Asian Patients
In a phase III trial reported in the Journal of Clinical Oncology, du Bois et al found that maintenance therapy with the VEGFR and PDGFR inhibitor pazopanib (Votrient) significantly prolonged progression-free survival vs placebo in women with ovarian cancer without progression after first-line...
Adding Cediranib to Olaparib Improves Progression-Free Survival and Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer
In a randomized phase II trial reported in The Lancet Oncology, Liu et al found a significant improvement in progression-free survival and an increase in toxicity with the addition of the antiangiogenic agent cediranib (VEGFR-1,-2,-3 inhibitor) to the PARP inhibitor olaparib in women with recurrent ...
Accuracy of Edinburgh Ovarian Tissue Cryopreservation Criteria in Girls and Young Women With Cancer
A study reported in The Lancet Oncology by Wallace et al evaluated the accuracy of criteria used for predicting ovarian insufficiency and offering ovarian tissue cryopreservation in young women with cancer at the Edinburgh Children’s Cancer Centre. Ovarian tissue cryopreservation with later...
Phase II Trial Shows Activity of Pemetrexed Plus Cisplatin in Treatment of Advanced, Persistent, or Recurrent Cervical Carcinoma
In a phase II Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Miller et al found that the combination of pemetrexed (Alimta) and cisplatin produced responses in the treatment of advanced, persistent, or recurrent cervical cancer. In the study, 54 patients from...
Study Identifies Prevalence of Uterine Malignancy and Endometrial Hyperplasia at Time of Morcellation for Hysterectomy
There is considerable concern that uterine morcellation as part of minimally invasive hysterectomy may result in the spread of undetected malignancies. In a study reported in JAMA, Wright et al identified a prevalence of 27 cases of uterine cancer and 7 cases of other gynecologic malignancies per...
ABCA Transporter Gene Expression Is Associated With Poor Outcome in Epithelial Ovarian Cancer
In a study reported in the Journal of the National Cancer Institute, Hedditch et al found that expression of ATP-binding cassette (ABC) transporter genes of the A subfamily (ABCA) had a significant impact on outcome in epithelial ovarian cancer. High ABCA1, Low ABCA5 Expression Analysis of gene...
Study Identifies Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
In a systematic review and meta-analysis reported in the Journal of the National Cancer Institute, Friebel et al attempted to identify factors that appear to modulate risk of breast and ovarian cancer in women who have inherited BRCA1 or BRCA2 mutations. Although the ability to perform...
Adding Antiangiopoietin Agent Trebananib to Paclitaxel Improves Progression-Free Survival in Recurrent Epithelial Ovarian Cancer
Trebananib inhibits angiogenesis by blocking the binding of angiopoietins 1 and 2 to the Tie2 receptor expressed on endothelial cells, a mechanism that differs from VEGF inhibitors and that involves a different signaling pathway. In the phase III TRINOVA-1 trial reported in The Lancet Oncology,...
Greater Progression-Free Survival Benefit of Maintenance Olaparib in BRCA-Mutant Platinum-Sensitive Recurrent Serous Ovarian Cancer
A recently reported phase II trial indicated that maintenance therapy with the PARP inhibitor olaparib significantly improved progression-free survival vs placebo in patients with platinum-sensitive serous ovarian cancer. As reported in The Lancet Oncology by Ledermann et al, a preplanned...
Gene Signatures Identified by Meta-Analysis Predict Survival and Suboptimal Debulking in Late-Stage Ovarian Cancer
As reported in the Journal of the National Cancer Institute, Riester et al have identified gene-expression signatures predictive of survival and debulking status in late-stage ovarian cancer. Study Details The study involved meta-analytic techniques using integrated data from 13 publicly...
Findings of AURELIA Trial Support Consideration of Bevacizumab/Chemotherapy in Carefully Selected Patients With Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvements in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Addition of Bevacizumab to Chemotherapy Improves Patient-Reported Outcomes in Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Adding Bevacizumab to Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer
Single-agent chemotherapy is standard in platinum-resistant ovarian cancer. In the open-label phase III AURELIA trial reported in the Journal of Clinical Oncology, Pujade-Lauraine et al found that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in...
Locoregional Progression of Cervical Cancer Follows Reverse Ontogenetic Sequence
In a study reported in The Lancet Oncology, Höckel et al demonstrated that locoregional progression of cervical cancer follows the reverse sequence of establishment of adult tissues in ontogeny. Ontogenetic staging was a better predictor of survival than pathologic staging. Previous work by...
Risk Factors for Gastrointestinal Adverse Events Studied in Setting of First-Line Bevacizumab/Chemotherapy for Ovarian Cancer
As reported in the Journal of Clinical Oncology, Burger et al assessed risk factors for gastrointestinal adverse events in women with advanced ovarian cancer receiving first-line bevacizumab (Avastin)/chemotherapy with or without bevacizumab maintenance or chemotherapy alone in the phase III...
Same Progression-Free Survival, Better Quality of Life With Lower-Dose Weekly vs Every-3-Week Carboplatin/Paclitaxel in Advanced Ovarian Cancer
In an open-label phase III trial (MITO-7) reported in The Lancet Oncology, Pignata et al found that while a lower-dose weekly carboplatin/paclitaxel regimen did not improve progression-free survival compared with standard every-3-week carboplatin/paclitaxel as first-line treatment of advanced...
Screening With Visual Inspection of Cervix After 4% Acetic Acid Could Reduce Cervical Cancer Mortality by 22,000 per Year in India
Cervical cancer is the leading cause of cancer death in women in India, a nation where large-scale Pap smear screening is not feasible. As reported in the Journal of the National Cancer Institute, Shastri et al have performed a large cluster-randomized study of education and screening of Indian...
Reduced Risk of Cervical Lesions Among Girls and Women 6 Years After Licensure of HPV Vaccine in Denmark
In a cohort study reported in the Journal of the National Cancer Institute, Baldur-Felskov et al found that there has been a significant reduction in cervical lesions among Danish girls and women receiving the quadrivalent human papillomavirus (HPV) vaccine during the first 6 years of its...
Adding Bevacizumab to Chemotherapy Improves Survival in Advanced Cervical Cancer
Retreatment with cisplatin has reduced effectiveness in patients with recurrent cervical cancer who have received cisplatin with radiation therapy. In a 2×2 factorial phase III trial reported in The New England Journal of Medicine, Tewari et al compared cisplatin/paclitaxel vs nonplatinum...
Aspirin and NSAID Use Reduce Risk of Invasive Epithelial Ovarian Cancer
In a study reported in Journal of the National Cancer Institute, Trabert et al in the Ovarian Cancer Association Consortium found that aspirin use and high-dose nonsteroidal anti-inflammatory drug (NSAID) use were associated with significant reductions in risk for ovarian cancer, with the greatest...
Promising Effects of High-Dose Parenteral Ascorbate in Ovarian Cancer
Oral ascorbate, or vitamin C, has been shown to be ineffective in cancer clinical trials. However, recent studies have indicated that millimolar concentrations of ascorbate achieved in blood and tissue with intravenous dosing is associated with cancer cell killing without harm to normal tissue. In...
Good Results With Telephone Genetic Counseling for Breast and Ovarian Cancer
As genomic testing becomes more common, genetic counseling is increasingly performed via telephone. BRCA1/2 mutation carries increased risk for breast and ovarian cancer. In a noninferiority study reported in the Journal of Clinical Oncology, Schwartz et al compared genetic counseling for BRCA1/2...
Quadrivalent HPV Vaccine Provides Poorer Protection in Women 18 and Older or With Abnormal Cytology
In a study reported in the Journal of Clinical Oncology, Mahmud et al evaluated the effectiveness of the quadrivalent human papillomavirus (HPV) vaccine against cervical dysplasia using population-based individual level data routinely collected in Manitoba. They found that a high proportion of...
Half of Patients With Stage I Pediatric Malignant Ovarian Germ Cell Tumors Can Be Spared Chemotherapy After Initial Surgery With Surveillance Strategy
In a Children’s Oncology Group study (AGCT0132) reported in the Journal of Clinical Oncology, Billmire et al found that overall survival can be preserved in patients with stage I pediatric malignant ovarian germ cell tumor with a strategy of initial surveillance after surgical resection....
No Benefit of Adding Tirapazamine to Cisplatin Chemoradiation in Locally Advanced Cervical Cancer
In a phase III intergroup trial (Gynecologic Oncology Group Protocol 219) reported in the Journal of Clinical Oncology, DiSilvestro et al in the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group evaluated the addition of the hypoxic cell sensitizer...
